Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 8.01 (Other Events). JADE301 showed selective IFN-ß neutralization, with 11.3 pM binding affinity and 13 pM pSTAT inhibition.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- JADE301 showed selective IFN-ß neutralization, with 11.3 pM binding affinity and 13 pM pSTAT inhibition
- Dermal fibroblast MX-1 inhibition reached 11 pM, approximately 8-fold more potent than dazukibart
- NHP pharmacokinetics supported infrequent subcutaneous dosing, including approximately 25-day half-life and modeled human bioavailability of 73%–75%
- GLP toxicology found JADE301 well tolerated at 50, 100 and 200 mg/kg every two weeks in NHPs
- Phase 1 trial planned for 24 healthy volunteers in fourth-quarter 2026, with interim data anticipated in second-half 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.